Risedronic acid

Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate.[1] It slows down the cells which break down bone.[1] It's used to treat or prevent osteoporosis, and treat Paget's disease of bone.[1] It is taken by mouth.[1]

Risedronic acid
Clinical data
Trade namesActonel, Atelvia, Benet, others
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only [1]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability0.63%
Protein binding~24%
MetabolismNone
Elimination half-life1.5 h
ExcretionKidney and fecal
Identifiers
IUPAC name
  • (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.116.436
Chemical and physical data
FormulaC7H11NO7P2
Molar mass283.113 g·mol−1
3D model (JSmol)
SMILES
  • OC(Cc1cccnc1)(P(=O)(O)O)P(=O)(O)O
InChI
  • InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15) N
  • Key:IIDJRNMFWXDHID-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

It was patented in 1984 and approved for medical use in 1998.[2]

Pharmacology
Relative potency[3]
Bisphosphonate Relative potency
Etidronate 1
Tiludronate 10
Pamidronate 100
Alendronate 100-500
Ibandronate 500-1000
Risedronate 1000
Zoledronate 5000

Society and culture

Brand names

It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet. It is also available in a preparation that includes a calcium carbonate supplement, as Actonel with Calcium.

Controversies

In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva.[4] The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on September 7, 2006, U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by denigrating Boniva". Judge Crotty wrote that "Roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented".[5]

In 2006, P&G faced controversy over its handling of clinical research involving risedronate (News Reports[6] and discussion).[7]

In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.

References
  1. "Actonel- risedronate sodium tablet, film coated". DailyMed. 1 November 2019. Retrieved 28 June 2022.
  2. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 523. ISBN 9783527607495.
  3. Tripathi KD (30 September 2013). Essentials of medical pharmacology (Seventh ed.). New Delhi. ISBN 9789350259375. OCLC 868299888.
  4. "P&G Press statement". Uk.pg.com. Retrieved 2013-03-01.
  5. "Boniva advertising 'not misleading' says US judge". Pharma Times. 8 September 2006.
  6. "Actonel Case Media Reports". Scientific Misconduct Wiki. Archived from the original on 2 February 2009.
  7. "Scientific Misconduct Blog". Scientific-misconduct.blogspot.com. Retrieved 2013-03-01.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.